Adaptimmune Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Series A Preferred Shares Preferred shares	Series A Preferred Shares	Common stock IPO	Common stock	Preferred shares	Additional paid in capital IPO	Additional paid in capital	Accumulated other comprehensive income (loss)	Accumulated foreign currency translation adjustments	Accumulated unrealized gains (losses) on available-for-sale debt securities	Accumulated deficit	IPO	Total
Balance at the beginning of the period at Jun. 30, 2014				$ 291			$ 32,512	$ 274			$ (30,120)		$ 2,957
Balance at the beginning of the period (in shares) at Jun. 30, 2014				181,370,100
Increase (Decrease) in Stockholders' Equity
Net loss											(22,058)		$ (22,058)
Issuance of common stock	$ 98,872	$ 98,872	$ 104			$ 175,885						$ 175,989
Issuance of common stock (in shares)			67,500,000
Beneficial conversion feature					$ (102,126)		102,126
Issuance of shares upon exercise of stock options (in shares)													0
Issuance of common stock upon conversion of preferred shares				$ 287	(11,481)		11,194
Issuance of common stock upon conversion of preferred shares (in shares)				175,841,800
Deemed dividends on preferred shares					$ 14,735						(14,735)
Other comprehensive loss, net of tax								(3,835)					$ (3,835)
Other comprehensive loss before reclassifications
Foreign currency translation adjustments													(3,835)
Share-based compensation expense							7,078						7,078
Balance at the end of the period at Jun. 30, 2015				$ 682			328,795	(3,561)			(66,913)		259,003
Balance at the end of the period (in shares) at Jun. 30, 2015				424,711,900
Increase (Decrease) in Stockholders' Equity
Net loss											(23,000)		$ (23,000)
Issuance of shares upon exercise of stock options (in shares)													0
Other comprehensive loss, net of tax								(4,578)					$ (4,578)
Other comprehensive loss before reclassifications
Foreign currency translation adjustments													(4,578)
Share-based compensation expense							3,568						3,568
Balance at the end of the period at Dec. 31, 2015				$ 682			332,363	(8,139)			(89,913)		234,993
Balance at the end of the period (in shares) at Dec. 31, 2015				424,711,900
Increase (Decrease) in Stockholders' Equity
Net loss											(71,579)		(71,579)
Issuance of shares upon exercise of stock options				$ 1			16						$ 17
Issuance of shares upon exercise of stock options (in shares)				63,192									63,192
Other comprehensive loss, net of tax								(6,110)					$ (6,110)
Other comprehensive loss before reclassifications
Foreign currency translation adjustments													(6,110)
Share-based compensation expense							8,821						8,821
Balance at the end of the period at Dec. 31, 2016				$ 683			341,200	$ (14,249)	$ (14,249)		(161,492)		166,142
Balance at the end of the period (in shares) at Dec. 31, 2016				424,775,092
Increase (Decrease) in Stockholders' Equity
Net loss											(70,138)		(70,138)
Issuance of common stock				$ 170			102,997						103,167
Issuance of common stock (in shares)				136,201,338
Issuance of shares upon exercise of stock options				$ 1			400						$ 401
Issuance of shares upon exercise of stock options (in shares)				1,142,904									1,142,904
Other comprehensive loss before reclassifications
Foreign currency translation adjustments									(3,618)				$ (3,618)
Unrealized holding losses on available-for-sale debt securities, net of tax of $0, $0, $0 and $0										$ (4,420)			(4,420)
Reclassification adjustment for losses on available-for-sale debt securities included in net income, net of tax of $0, $0, $0 and $0										646			646
Share-based compensation expense							10,804						10,804
Balance at the end of the period at Dec. 31, 2017				$ 854			$ 455,401		$ (17,867)	$ (3,774)	$ (231,630)		$ 202,984
Balance at the end of the period (in shares) at Dec. 31, 2017				562,119,334